Phibro Q4 net sales up 7% to $273.2M; FY2025 guidance sees 10% adjusted EBITDA growth

PHIBRO ANIMAL HEALTH CORP

2024-FY EPS reported $0.06 revenue$1,017,679,000

Q4 GAAP net income of $0.8M ($0.02 EPS) vs $11.5M ($0.28 EPS) YoY; adjusted EPS $0.41 (+10%).
Full-year net sales $1,017.7M (+4%); adjusted EBITDA $111.2M (-1%); adjusted EPS $1.19 (-1%).
FY2025 guidance: net sales $1.04B-$1.09B, adjusted EBITDA $118M-$126M, adjusted EPS $1.22-$1.37.
Free cash flow $46.4M; total debt $489.1M; cash & short-term investments $114.6M; gross leverage 4.4x.
Guidance excludes proposed Zoetis MFA acquisition; company notes strength in Q4 Animal Health segment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.